Tasigna
Tasigna

12.75
This complex This medication addresses key cellular proliferation markers in the blood.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Nilotinib
Reference Brand
Nilotinib
Product Origin
Generic Alternative
Reference Manufacturer
Novartis
Product Form
Capsule
Regulatory Classification
Rx
Primary Category
Oncology Support
Product Category
Tyrosine Kinase Inhibitor
Pharmacological Class
Antineoplastic
Clinical Indications
Manufacturer Description
Formulated for chronic myeloid leukemia to target cancer cell pathways and support oncology management.
Mechanism of Action
Nilotinib inhibits the Bcr-Abl tyrosine kinase protein, which is produced by the Philadelphia chromosome in chronic myeloid leukemia cells. This action stops the proliferation of leukemia cells and induces apoptosis.
Route of Administration
Oral
Onset Time
1–3 months
Duration
Ongoing use required
Contraindications
Hypersensitivity to nilotinib, Long QT syndrome, Hypokalemia, Hypomagnesemia
Severe Adverse Events
Qt prolongation, Myelosuppression, Pancreatitis — requires immediate medical attention
Common Side Effects
Nausea, Rash, Headache
Uncommon Side Effects
Fatigue, Pruritus, Constipation
Drug Interactions
Grapefruit, Ketoconazole, Warfarin, Alcohol, Proton Pump Inhibitors
Pregnancy Safety Warnings
FDA Category D: High risk of fetal harm. Breastfeeding: Not recommended.
Age Restrictions
Safety and efficacy established in pediatric patients one year and older.
Storage Guidelines
Store at room temperature.
Related Products
Gleevec, Sprycel
Information related to Tasigna is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
Where to order Antidepressants - Buy Escitalopram UK